Abstract: A ferroelectric, liquid-crystalline polymer is composed of repeating units of the formula (I) ##STR1## in which Y.sup.1 =H, CH.sub.3 or FY.sup.2 =H or FR.sup.1 = ##STR2## or an achiral alkyl having 2 to 16 carbon atoms, and R.sup.3 =H or CH.sub.3R.sup.2 =CH.sub.3, Cl or CNg and h=an integer from 0 to 10a=2 to 20, preferably 6 to 12b,c,d,e and f=0 or 1, where d+e+f=2 or 3A.sup.1,A.sup.2 and A.sup.3 =for example, 1,4-phenylene in which one or two hydrogen atoms may be substituted by F, Cl and/or CN, 1,4-cyclohexylene andM.sup.1,M.sup.2 and M.sup.3 =for example, CO--O or O--CO.These liquid-crystalline polymers have short response times and high resistance to mechanical stresses. They can be prepared by free-radical polymerization.

Abstract: Compounds of the formula IR.sup.1 --A.sup.1 --Z.sup.1 --A--O--R.sup.2in whichR.sup.1 and R.sup.2, independently of one another, are each alkyl having 1 to 9 C atoms, in which, in addition, one or two CH.sub.2 groups may be replaced by --O--, --CO--, --O--CO--, --CO--O-- and/or --CH.dbd.CH--, where two O atoms are not linked directly to one anther, or one of the two groups R.sup.1 and R.sup.2 is alternatively H,Z.sup.1 is --CH.sub.2 --O--, --OCH.sub.2 --, --CH.sub.2 CH.sub.2 -- or a single bond,A.sup.1 is trans-1,4-cyclohexylene in which, in addition one or two nonadjacent CH.sub.2 groups may be replaced by O and/or S, or 1,4-cyclohexenylene, andA is unsubstituted or fluorine-substituted 1,4-phenylene, can be used as components of liquid-crystalline dielectrics containing at least three liquid-crystalline compounds for shortening the switch-on time T.sub.

Abstract: Compounds having a terminal alkyloxypropenyl group of the general formula ##STR1## wherein rings A.sup.1 and A.sup.2 each independently represent unsubstituted or halogen-substituted 1,4-phenylene, in which optionally 1 CH group or 2 CH groups is/are replaced by nitrogen, or trans-1,4-cyclohexylene or trans-1,3-dioxane-2,5-diyl; n is either 0 or 1; Z.sup.1 and Z.sup.2 each independently signify a single covalent bond or --CH.sub.2 CH.sub.2 --, --COO--, --OOC--, --OCH.sub.2 --, --CH.sub.2 O--, --(CH.sub.2).sub.4 --, --O(CH.sub.2).sub.3 --, --(CH.sub.2).sub.3 O--, the trans form of --O--CH.sub.2 --CH.dbd.CH--, --CH.dbd.CH--CH.sub.2 --O--, --(CH.sub.2).sub.2 CH.dbd.CH-- or --CH.dbd.CH--(CH.sub.2).sub.2 --; R.sup.1 denotes an alkyl group; R.sup.2 represents halogen, cyano, trifluoroacetyl, optionally fluorine-substituted alkyl with 1 to 12 carbon atoms, in which optionally 1 --CH.sub.2 -- group or 2 non-adjacent --CH.sub.2 -- groups is/are replaced by oxygen and/or a --CH.sub.2 CH.sub.

Abstract: The novel liquid-crystalline mixtures (in the case of ferroelectric behavior they additionally contain an optically active compound as dope) are based on at least two mixture components of the general formula (I) and at least one carboxylate of the general formula (II), (III) or (IV). ##STR1## The mixtures have favorable properties for use in electrooptical display elements, such as high contrast, low melting point and short switching times.

Abstract: An oxygen absorbent composition containing a linear hydrocarbon polymer having one or more unsaturated groups or a mixture of a linear hydrocarbon polymer having one or more unsaturated groups with an unsaturated fatty acid compound and an oxidation promoter as essential components and optionally containing a basic substance and/or an adsorption substance; an oxygen absorbent parcel formed by packing the oxygen absorbent composition with a gas-permeable packing material; and a method of preserving an article by means of same.

Abstract: It is an object of the present invention to provide a polymer dispersion-type liquid crystal display device having a high holding rate, a superior display quality and a high reliability; the liquid crystal display device according to the present invention composed of (i) a display electrode substrate, (ii) a counter electrode substrate and (iii) a liquid crystal layer interposed between said display electrode substrate and said counter electrode substrate, in which liquid crystals having a positive anisotropy in dielectric constant are dispersed in a transparent polymer; the transparent polymer is a photo cation polymerization setting-type transparent polymer and the liquid crystals are fluorine-containing aryl compounds.

Abstract: The invention relates to a liquid-crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, characterized in that it contains one or more compounds of the general formula I ##STR1## in which L is H or F, X is F, Cl, CF.sub.3, OCF.sub.3 or OCHF.sub.2, and R is alkyl, oxaalkyl, fluoroalkyl or alkenyl, in each case having up to 7 carbon atoms.

Abstract: A gadolinium (3.sup.+) complex of polyamine polyacetate, comprising a polyamine nucleus having a pendant boron-containing substituent on one of the nitrogen or carbon atoms of the polyamine nucleus. The boron-gadolinium compound may suitably be of the formula: ##STR1## wherein: is a polyamine coordination structure capable of covalently bonding the substitutents R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and of complexing with Gd;R.sub.1, R.sub.2, and R.sub.3 are independently selected from carboxyl, carboxylic salt groups, carboxylic ester groups, and carboxylate anion;R.sub.4 is a boron-containing group; andx is a number from zero to 4.

Abstract: A group of functionalized polyamine chelants that form complexes with rhodium are disclosed. The rhodium complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.

Abstract: A method for neutralizing acidic species and inhibiting the deposition of amine acid salts on the internal surfaces of elevated temperature processing units in a petroleum refinery comprising adding to the hydrocarbon liquid being processed therein a tertiary amine, including trimethylamine and triethylamine.

Abstract: A composition comprising a .beta.-branched aldol ether alcohol having the structure: ##STR1## wherein X=5 to 8, at least one surfactant and water which is useful to prevent or reduce foam present in the aqueous medium of paper processing operations.

Abstract: A process for producing a sulfur sorbent composition in a mixer having a mixer paddle an energy supply is disclosed which includes hydrating an alkaline earth metal oxide in an aqueous solution containing a promoting additive selected from a group consisting of urea and mixtures of urea with a water soluble iron salt under high intensity mixing conditions with the mixer wherein the mixer is operated at a mixer paddle tip velocity of at least 500 ft/min and a mixer energy input of at least 3.5 kW-h per ton of sorbent so as to produce a sulfur sorbent composition having the following physical and chemical properties: alkaline earth metal (wt.%)--40-52, molar ratio of promoting additive to alkaline earth metal--0.001-0.2, bulk density (g/ml)--0.35-0.75, surface area (m.sup.2 /g)--5-25, pore volume (cc/g)--0.05-0.14 and mean particle size (.mu.m)--4.

Abstract: The present invention relates to a composition comprising a antimicrobially effective amount of a combination of an pyrithione and a lipopeptide antibiotic. Also disclosed is an aqueous industrial functional fluid comprising an aqueous base fluid medium and an antimicrobially effective amount of a combination of a pyrithione and a lipopeptide antibiotic. Also disclosed is a process for providing biocidal activity to an aqueous industrial functional fluid which comprises incorporating into said fluid an antimicrobially-effective amount of a combination of a pyrithione and a lipopeptide antibiotic.

Abstract: An optically active compound represented by the following formula (I): ##STR1## wherein R.sub.1 denotes an alkyl or alkoxy group having 1-18 carbon atoms; R.sub.2 denotes an alkyl group having 1-12 carbon atoms; A denotes ##STR2## X denotes and C* denotes an optically active asymmetric carbon atom. The optically active compound, when included as a component, provides a ferroelectric liquid crystal composition or device showing an improved electro-field response characteristic.

Abstract: Compounds of the formula IR.sup.1 --A.sup.1 --A.sup.2 --R.sup.2 IwhereinR.sup.1 and R.sup.2 are each alkyl with 1-15 C atoms, and wherein one or two non-adjacent CH.sub.2 groups can also be replaced by --O--, --S--, --CO--, --O--CO--, --CO--O--, --CO--S--, --S--CO--, --CHHalogen--, --CHCN-- and/or --CH.dbd.CH--,A.sup.1 is 1,4-phenylene, trans-1,4-cyclohexylene or a single bond andA.sup.2 is ##STR1## in which Z is --O--CO--, --CO--O--, --S--CO--, --CO--S--, CH.sub.2 O--, --OCH.sub.2 -- or --CH.sub.2 CH.sub.2 --, with the proviso that, if A.sup.1 is a single bond, A.sup.2 is ##STR2## are suitable as components of chirally tilted smectic liquid crystal phases.

Abstract: This invention relates to the usage of anticoagulant peptide derivatives that are iodinated.

Abstract: Radiopharmaceuticals consisting essentially of a lipophilic, charge neutral radionuclide complex of a diaminedithiol ligand having 1-4 ester groups of the formula --A--COOR where A is a straight or branched chain alkylene of 0-10 carbon atoms and R is an alkyl group of 1-10 carbon atoms are useful in radioimaging brain perfusion in primates. Ester-substituted diaminedithiols in sterile, pharmaceutically acceptable form, and kits of the diaminedithiols and sterile, non-pyrogenic reducing agents for reducing preselected radionuclides are also provided. Technetium-99m is a preferred radionuclide.

Abstract: A process is shown for treating flue or exhaust gases in order to remove sulfur oxides and hydrochloric acids in which calcium hydroxide having a surface area of at least 25 m.sup.

Abstract: A silver halide photographic emulsion is disclosed, comprising silver halide grains containing a first silver halide phase containing at least 3 mol % of silver iodide and having a completely uniform silver iodide distribution, and a second silver halide phase having at least 5 dislocation lines.

Abstract: A method is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication employing a cholesterol lowering drug such as an HMG CoA reductase inhibitor alone and/or an inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil; employing an ACE inhibitor alone such as captopril or ceranapril; or a combination of a cholesterol lowering drug and an ACE inhibitor.